Targeting TYRO3 inhibits epithelial–mesenchymal transition and increases drug sensitivity in colon cancer

Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location

(2013) Talia Golan et al.   CANCER

Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration

(2013) Floor A.M. Duijkers et al.   GENE

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer

(2013) Eva Budinska et al.   JOURNAL OF PATHOLOGY

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

Immune Modulation of Vascular Resident Cells by Axl Orchestrates Carotid Intima-Media Thickening

(2012) Janice Gerloff et al.   AMERICAN JOURNAL OF PATHOLOGY

Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery

(2011) Ruei-Min Lu et al.   BIOMATERIALS

Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer

(2011) E. Avilla et al.   CANCER RESEARCH

Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma

(2010) Xianzhou Song et al.   CANCER

A genomic screen identifies TYRO3 as a MITF regulator in melanoma

(2009) S. Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of CD151 by Hypoxia Controls Cell Adhesion and Metastasis in Colorectal Cancer

(2008) C.-W. Chien et al.   CLINICAL CANCER RESEARCH